STOCK TITAN

Iridex - IRIX STOCK NEWS

Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.

Overview of Iridex Corporation

Iridex Corporation (symbol: IRIX) is a global enterprise renowned for its innovative and versatile laser-based medical systems in the ophthalmology and medical device markets. With a clear focus on noninvasive treatment solutions, the company excels in developing, manufacturing, and marketing advanced laser systems, delivery devices, and consumable instrumentation. By integrating key industry technologies including laser-based systems, MicroPulse technology, and precision delivery tools, Iridex firmly establishes itself as a technical expert in the field.

Core Business and Technological Expertise

At its core, Iridex is dedicated to addressing sight-threatening eye conditions through state-of-the-art laser procedures. The company leverages its proprietary MicroPulse technology to deliver treatments that are both safe and effective. This nonincisional approach provides significant clinical advantages, especially for patients with glaucoma, diabetic macular edema, and other retinal disorders. The technology is embedded in a robust product portfolio featuring lasers, laser consoles, delivery devices, and consumable instruments, all designed to optimize patient outcomes and treatment precision.

Product Portfolio and Market Applications

Iridex offers an extensive range of products that support various clinical specialties. The product lines include:

  • Laser Systems and Consoles: Engineered for precision treatment delivery in ophthalmologic surgeries and procedures.
  • Delivery Devices and Consumables: Instruments designed to not only enhance procedural accuracy but also to maintain high levels of efficiency during treatments.
  • Specialized Procedural Tools: Equipment that supports innovative treatment methodologies, particularly in glaucoma management and retinal therapies.

This diverse product suite enables healthcare providers to select the appropriate tools for both routine and complex procedures.

Global Operations and Revenue Model

Iridex operates through a streamlined business model that focuses on one primary reportable segment—ophthalmology. Its revenue streams derive from the direct sales of medical systems and instruments, along with supplemental service and support activities. Products are marketed and sold directly in the United States via a dedicated sales force, while international customers are reached through a network of independent distributors, covering territories in Europe, the Americas, and other regions. This balanced revenue model underscores the company's resilience and adaptability in a competitive global market.

Commitment to Customer Success and Support Excellence

Beyond its advanced product offerings, Iridex is committed to comprehensive technical, clinical, and service support. This commitment ensures that customers—ranging from large healthcare institutions to specialized clinics—receive thorough training and ongoing assistance in deploying complex laser-based procedures. The company's emphasis on technical expertise and hands-on support underlines its dedication to maintaining high standards of clinical performance and customer satisfaction.

Position in the Competitive Landscape

Iridex distinguishes itself within a highly specialized field by combining cutting-edge technological innovation with a deep commitment to clinical excellence. While other players in the medical device market may offer alternative treatment solutions, Iridex's focus on laser-based systems uniquely positions it as a trusted partner for ophthalmologists and healthcare providers around the world. Its products are recognized for their safety, precision, and repeatability, making them a cornerstone in modern ophthalmic care.

Expertise, Innovation, and Industry Impact

Utilizing detailed technical knowledge and a strategic market approach, Iridex has built a reputation for sustained performance in challenging healthcare environments. Its innovative systems not only meet established medical standards but also push the envelope in terms of procedural efficacy and treatment customization. For financial analysts and industry experts, the company's operational model and supply chain efficiency offer valuable insights into its competitive dynamics in the global medical apparatus segment.

Conclusion

In summary, Iridex Corporation stands as a comprehensive provider of advanced laser-based medical systems. Its steadfast dedication to innovation, coupled with integrated support programs and a strong global market presence, positions the firm as a significant contributor within the ophthalmology and broader medical device sector. With detailed attention to technical detail and a focus on clinical effectiveness, Iridex continues to provide safe, repeatable, and effective solutions to bring about superior patient outcomes.

Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) reported a 6% increase in full-year revenue to $57 million for 2022, driven by strong sales of its Cyclo G6 glaucoma products. In Q4 2022, total revenue was $15.2 million, with a record 16,400 Cyclo G6 probes sold, up 9% year-over-year. However, retina product revenue declined by 11% to $8.1 million. The company received FDA clearance for new laser systems in late 2022 and early 2023. Despite a net loss of $7.5 million for 2022, with a projected revenue of $57 million to $59 million for 2023, Iridex anticipates growth in Cyclo G6 probe sales between 9% and 12%. Cash reserves stand at $13.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.85%
Tags
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX), a leader in ophthalmic laser-based medical products, announced its participation in the 35th Annual Roth Conference in Laguna Niguel, CA. Management will present on March 14, 2023, at 11:00 am PT. Interested individuals can view a live and archived webcast of the presentation on the company's website.

Iridex focuses on innovative treatments for glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology. The company's products are distributed in over 100 countries, emphasizing their global reach and commitment to addressing serious eye conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
conferences
-
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) announced the publication of Part 2 of the evidence-based guidelines for MicroPulse Transscleral Laser Therapy (TLT) at the 2023 American Glaucoma Society meeting in Austin, Texas. This guide, created by a panel of ten glaucoma experts, covers critical aspects such as anesthesia, surgical technique, and expected outcomes. It builds on Part 1, focusing on dosimetry and patient selection. Attendees can also view Dr. Syril Dorairaj's e-poster on MicroPulse TLT outcomes and demo the Sweep Management Software designed to optimize surgical techniques. Iridex continues to lead in ophthalmic laser-based treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) will release its financial results for Q4 and full year 2022 after the market closes on March 9, 2023. The management team will host a conference call at 2:00 PM PT / 5:00 PM ET to discuss the results. Investors can access the live and recorded webcast on the Company’s website. Iridex specializes in innovative ophthalmic laser-based products for treating glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology. Their products are marketed in the U.S. and over 100 countries worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
conferences earnings
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) announced preliminary financial results for the fourth quarter and full year ended December 31, 2022. Fourth quarter revenue is projected at $15.1 million to $15.3 million, unchanged year-over-year. The company achieved a record sale of 16,400 Cyclo G6 probes, an 8% increase from the previous year. Full year revenue is expected to be between $56.9 million and $57.1 million, reflecting a 6% growth. Cash and equivalents were approximately $13.9 million, with operating cash usage of $1.2 million in Q4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.98%
Tags
-
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX), a leader in ophthalmic laser-based medical products, announced its participation in a fireside chat with Stifel's equity research analyst. This discussion is scheduled for December 8, 2022, at 9:00 a.m. PT / 12:00 p.m. ET. The event will be accessible via a live and archived webcast on the Company’s website. Iridex specializes in innovative laser systems for treating glaucoma and retinal diseases, using its proprietary MicroPulse® technology. The Company's products are distributed both in the U.S. and over 100 countries worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
conferences
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) reported a strong third quarter for 2022, achieving record revenue of $14.6 million, a 10% increase from the previous year. The company's gross margin rose to 44.1%, and the Cyclo G6 product family generated $3.5 million in revenue, boosted by 13,680 probes sold. Retina product revenue also increased to $8.8 million, a 13% rise year-over-year. However, the net loss decreased to $1.8 million, or $0.11 per share. The company expects total revenue for 2022 to reach $56 million to $58 million, representing 4% to 8% growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
-
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) will release its third-quarter 2022 financial results on November 10, 2022, after market close. A conference call with management will follow at 2:00 p.m. PT / 5:00 p.m. ET. Investors can access the live and recorded webcast on the Company’s website.

Iridex specializes in innovative ophthalmic laser-based medical products, primarily treating glaucoma and retinal diseases. Their products are distributed in the U.S., Germany, and over 100 other countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
conferences earnings
-
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) is showcasing its innovative glaucoma treatment technologies at the 2022 American Academy of Ophthalmology annual meeting. The company introduces the Sweep Management Software for its Cyclo G6 Glaucoma Laser System, enhancing the precision of MicroPulse Transscleral Laser Therapy (TLT). This non-incisional treatment can reduce intraocular pressure by 25% to 45%. Iridex emphasizes its commitment to advancing glaucoma care through educational presentations and demonstrations at booth #5139.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
none
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, set for August 31, 2022, at 1:00 p.m. PT / 4:00 p.m. ET. During the virtual event, management will present the company's innovative ophthalmic laser-based medical products aimed at treating glaucoma and retinal diseases. A live webcast of the presentation will be available, with an archived version accessible on the Iridex website for further insights into their MicroPulse® technology and product offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
conferences

FAQ

What is the current stock price of Iridex (IRIX)?

The current stock price of Iridex (IRIX) is $0.9908 as of April 1, 2025.

What is the market cap of Iridex (IRIX)?

The market cap of Iridex (IRIX) is approximately 16.5M.

What is the core focus of Iridex Corporation?

Iridex specializes in the development, manufacturing, and marketing of innovative laser-based medical systems and delivery devices, primarily for the ophthalmology market.

Which technologies underpin Iridex's product portfolio?

The company leverages proprietary technologies such as MicroPulse® to deliver safe, effective, and repeatable laser treatments, particularly for glaucoma and retinal diseases.

How does Iridex generate revenue?

Revenue is generated through direct sales of laser consoles, delivery devices, consumables, and from supplemental services including technical support and clinical training.

In which markets does Iridex operate?

Iridex operates globally, with significant market presence in the United States and coverage in Europe, the Americas, and other key international regions via independent distributors.

What distinguishes Iridex's products from competitors?

Iridex’s products are distinguished by their advanced laser technology, precision delivery systems, and the clinical efficacy demonstrated by its proprietary MicroPulse® technology.

Who are the primary customers of Iridex?

The primary customers include hospitals, specialized clinics, and healthcare providers focusing on ophthalmology and related medical fields.

What kind of support does Iridex offer to its customers?

Iridex offers comprehensive technical, clinical, and service support programs to ensure optimal product performance and customer success in treatment applications.

How is Iridex positioned in the competitive landscape?

Iridex is recognized for its expertise in laser-based systems and maintains a competitive edge with its innovative technologies and extensive global distribution network, making it a trusted partner in ophthalmic care.
Iridex

Nasdaq:IRIX

IRIX Rankings

IRIX Stock Data

16.47M
13.35M
20.67%
19.45%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW